Dr. Lara on Epacadostat Plus Pembrolizumab in RCC
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).
The phase Ib/II trial showed encouraging response rates and safety signals for this combination, particularly with patients who had minimally pretreated disease.
The confirmed response rate was 47%. In this study, only 17% of patients experienced grade 3 or higher toxicity, which is what is expected with single agent checkpoint inhibitor therapy.
